Preclinical Assessment of Low Doses of Cisplatin in the Management of Acute Promyelocytic Leukemia

Cis-diamminedichloroplatinum (II) (cisplatin) is the most widely used chemotherapeutic drug for various cancers, but its effectiveness is limited by tumor cell resistance and the severe side effects it causes. Since high level of cisplatin is cytotoxic to both cancer and normal cells, the goal of th...

Descripción completa

Detalles Bibliográficos
Autores principales: Dasari, Shaloam R, Velma, Venkatramreddy, Yedjou, Clement G, Tchounwou, Paul B
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2015
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4758698/
https://www.ncbi.nlm.nih.gov/pubmed/26900603

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4758698/
https://www.ncbi.nlm.nih.gov/pubmed/26900603

Ejemplares similares